Evidence map›Paper›PMID 30214088›Full record

ArticleNagoya journal of medical science2018

Comparison of twice a day and three times a day meropenem administration in elderly patients in a Japanese community hospital.

Kouji Aimiya, Takayoshi Mamiya, Katsunori Tabuchi, Toshiyuki Kita, Masayuki Hiramatsu

Open access · greenAbstract read
In one paragraph

Article in Nagoya journal of medical science, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 70% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Kouji AimiyaDepartment of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan.
Takayoshi MamiyaDepartment of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan.
Katsunori TabuchiDepartment of Pharmacy, National Hospital Organization Kanazawa Medical Center, 1-1 Shimo-ishibiki-machi, Kanazawa 920-8650, Japan.
Toshiyuki KitaDepartment of Pulmonary Medicine, National Hospital Organization Kanazawa Medical Center, 1-1 Shimo-ishibiki-machi, Kanazawa 920-8650, Japan.
Masayuki HiramatsuDepartment of Chemical Pharmacology, Graduate School of Pharmaceutical Sciences, Meijo University, 150 Yagotoyama, Tempaku-ku, Nagoya 468-8503, Japan.
Meijo University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Meropenem (MEPM) is a broad-spectrum antibiotic prescribed to patients with moderate or severe pneumonia. It is well recognized that appropriate medicine reduces the burden on not only young patients but elderly ones as well. We enrolled 56 patients aged 75 and over who were diagnosed with moderate or severe pneumonia (body temperature: ≧37.5 °C; white blood cell (WBC) count: ≧10,000/μL; C-reactive protein (CRP): ≧4 mg/dL) on the basis of Clinical Evaluation Methods for New Antimicrobial Agents to Treat Respiratory Infections defined by the Japanese Society of Chemotherapy, at the National Hospital Organization Kanazawa Medical Center from January 1, 2007 to May 31, 2010. Forty-two patients were given MEPM twice a day and 14 were given the same drug three times a day in a Japanese community hospital. After four days, the three times a day group showed significant decreases in body temperature, WBC count, and CRP level, which are commonly used indices for evaluating therapeutic effects. Similarly, the twice a day group showed decreases of those indices, and both treatments had no serious adverse effects. Simulation analysis based on the pharmacokinetics-pharmacodynamics (PK/PD) theory revealed that both treatments effectively inhibited the activities of

Indexed as

AgedAged, 80 and overAnti-Bacterial AgentsFemaleHaemophilus influenzaeHospitals, CommunityHumansJapanMaleMeropenemPneumoniaProvidenciaStaphylococcus aureusStreptococcus pneumoniaeAnti-Bacterial AgentsMeropenemelderly patientmeropenempneumonia

Identifiers

PMID30214088
PMCPMC6125661
OpenAlexW3024996056

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.